Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".
作者信息
Garcia-Cremades Maria, Solans Belen P, Hughes Emma, Ernest Jacqueline P, Wallender Erika, Savic Radojka M
机构信息
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Department of Clinical Pharmacy, University of California, San Francisco, California, USA.
出版信息
Clin Pharmacol Ther. 2020 Aug;108(2):189. doi: 10.1002/cpt.1873. Epub 2020 May 20.
Abstract
摘要
相似文献
1
Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".对《SARS-CoV-2治疗药物的定量临床药理学输入应基于可靠数据》的回应。
Clin Pharmacol Ther. 2020 Aug;108(2):189. doi: 10.1002/cpt.1873. Epub 2020 May 20.
2
Quantitative Clinical Pharmacology Input to SARS-CoV-2 Therapeutics Should Be Based on Robust Data.用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）治疗的定量临床药理学投入应基于可靠的数据。
Clin Pharmacol Ther. 2020 Aug;108(2):187. doi: 10.1002/cpt.1872. Epub 2020 May 20.
3
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.伊维菌素，一种治疗新型冠状病毒/新冠肺炎的新候选药物。
Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
4
Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).无症状冠状病毒感染：中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2（新型冠状病毒肺炎）
Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.
5
From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.从严重急性呼吸综合征冠状病毒到严重急性呼吸综合征冠状病毒2：法医传染病尸检的应对与挑战
Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.
6
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1233-1234. doi: 10.1016/S1473-3099(20)30467-9. Epub 2020 Jul 14.
7
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1233. doi: 10.1016/S1473-3099(20)30463-1. Epub 2020 Jul 14.
8
Challenges and issues of SARS-CoV-2 pool testing.新型冠状病毒2019（SARS-CoV-2）混合检测的挑战与问题
Lancet Infect Dis. 2020 Nov;20(11):1232-1233. doi: 10.1016/S1473-3099(20)30516-8. Epub 2020 Jul 14.
9
A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.武汉以外与一次乔迁宴相关的新冠肺炎聚集性病例。
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.034. Epub 2020 Apr 10.
10
Authors' response: Plenty of coronaviruses but no SARS-CoV-2.作者回应：存在大量冠状病毒，但没有严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。
Euro Surveill. 2020 Feb;25(8). doi: 10.2807/1560-7917.ES.2020.25.8.2000197.
本文引用的文献
1
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.在体外筛选美国食品药品监督管理局批准的化学药物库时发现了一些可能抑制 SARS-CoV-2 复制的化合物。
Sci Rep. 2020 Aug 4;10(1):13093. doi: 10.1038/s41598-020-70143-6.
2
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
3
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
4
Advancing the development of new tuberculosis treatment regimens: The essential role of translational and clinical pharmacology and microbiology.推进新型结核病治疗方案的研发：转化医学与临床药理学及微生物学的重要作用。
PLoS Med. 2019 Jul 5;16(7):e1002842. doi: 10.1371/journal.pmed.1002842. eCollection 2019 Jul.
Zotero 插件